We are proud and pleased to introduce SPRAVATO™ nasal spray, a different kind of prescription medicine for adults with treatment-resistant depression (TRD) and the first one in decades approved by the FDA.
SPRAVATO is only available under a Risk Evaluation and Mitigation Strategy (REMS) program. The REMS program requires that you are monitored by a healthcare provider for two full hours after taking SPRAVATO and that you do not drive or operate heavy machinery until you get a full night of rest. You will need to make arrangements for transportation to and from Columbia Associates in Psychiatry on the days of treatment.
The most common side effects reported by patients in clinical trials include dissociation (41%), dizziness (29%), nausea (28%), sedation (23%), and spinning sensation (23%). Less-encountered side effects include reduced sense of touch and sensation, anxiety, lack of energy, increased blood pressure, vomiting, and feeling drunk.
Knowing how to prepare yourself for SPRAVATO treatment and having complete instructions for proper personal usage are critical to your treatment success. To that end, we have prepared two helpful documents in PDF format. One explains how to prepare for your SPRAVATO treatment days and the second provides detailed, illustrated instructions for proper SPRAVATO usage.
Meet Dr. Spivack
We’re honored to have had the opportunity to use TMS therapy to help our patients, and we look forward to being able to provide another 1 million treatments!
has been Honorably Mentioned in Worldwide Leaders in Healthcare. She was also awarded the Top Nurse Practitioner Award for 2017 by the International Nurses Association.